Clinical genetic testing is a standard diagnostic practice for testing children with unexplained developmental delay/intellectual disability, autism spectrum disorders and multiple congenital ...

CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to the underserved problem of recurrent pregnancy loss as well as to prenatal testing. CombiMatrix performs microarray assays ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

New York, NY—A large, multi-center clinical trial led by researchers from Columbia University Medical Center (CUMC) shows that a new genetic test resulted in significantly more clinically relevant ...

CombiMatrix, a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, today announced that it has entered into a strategic partnership with the ...

The DNA microarray market is witnessing steady growth due to the rising demand for advanced genomic research, personalized medicine, and early disease diagnosis. The increasing prevalence of cancer, ...

The identification of clinically relevant genomic dosage anomalies assists in accurate diagnosis, prognosis, and medical management of affected individuals. Technological advancements within the field ...

Ariosa Diagnostics announced that its scientists have successfully tested and implemented a microarray DNA quantification method for Ariosa's Harmony Non-Invasive Prenatal Test SAN JOSE, California, ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray as the new standard practice for genetic evaluation of children with unexplained ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray (CMA) as the new standard practice for genetic evaluation of children with ...